IDYA
IDYA clinical trials: IDEAYA Biosciences, Inc.
Every trial on ClinicalTrials.gov where IDEAYA Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 11
- As lead sponsor
- 1
- As collaborator
- 3
- Primary completions as lead sponsor, next 90 days
IDYA on the catalyst calendar · IDYA registry changes
- Primary completion Apr 30, 2028Sponsor estimatePhase 1NCT07277413A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsIDEAYA Biosciences · NSCLC AdenocarcinomaRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2034Sponsor estimatePhase 3NCT07804186Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaIDEAYA Biosciences · Uveal MelanomaRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences · Esophageal Squamous Cell CarcinomaRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2029Sponsor estimatePhase 1NCT07540572A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced...IDEAYA Biosciences · CancerRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 1NCT05787587A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsIDEAYA Biosciences · Advanced or Metastatic Solid TumorsActive, not recruitingIDYALeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 1/Phase 2NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerIDEAYA Biosciences · Small-cell Lung CancerRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1/Phase 2NCT03947385Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsIDEAYA Biosciences · Metastatic Uveal MelanomaRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2030Sponsor estimatePhase 3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences · Uveal MelanomaRecruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT04794699Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionIDEAYA Biosciences · Solid TumorActive, not recruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 2NCT05907954(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaIDEAYA Biosciences · Uveal MelanomaActive, not recruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2027Sponsor estimatePhase 2/Phase 3NCT05987332IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaIDEAYA Biosciences · Metastatic Uveal MelanomaActive, not recruitingIDYALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2026Sponsor estimatePhase 1/Phase 2NCT06710847A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other...GlaxoSmithKline · Neoplasms, ColorectalActive, not recruitingGSKLeadIDYACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner